Under the agreements, Bioké, a business unit of Cell Signaling Technology Europe, will distribute the two platforms in the Netherlands, Belgium, and Luxembourg.
HalioDx operates a CLIA-certified lab through which OncoDNA will provide it molecular testing services to drugmakers studying precision cancer therapies.
Osang is seeking US Food and Drug Administration Emergency Use Authorization for its PCR-based SARS-CoV-2 diagnostic kit and plans to distribute it to US airports.
Boston-based NanoView aims to use its ExoView platform to understand the biological role of extracellular vesicles and their use as disease biomarkers.
The agreement will allow life science researchers in Switzerland better access to the image-based CellRaft AIR system's instrument, consumables, and support.
Oncocyte will receive upfront cash payments after transferring and installing DetermaRx, in addition to certain tests after it achieves inclusion in the US Comprehensive Cancer Network.
The products analyze various datasets including a patient's genetic and metabolic profiles, clinical history, and demographics to inform prescribing decisions.
Yourgene's Taipei subsidiary will promote the Take2 Prophecy test in Taiwan and will establish a clinical network for the collection of patient blood samples.
The kits can be used to barcode molecules for linked-read analysis to enable characterization of long-range information from short-read sequencing platforms.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
